非小细胞肺癌中CDK4I/P16的表达及与淋巴结转移关系的研究

CDK41/P16 EXPRESSION AND IT'S CORRELATION WITH METASTATIC CANCER OF LYMPH NODE IN HUMAN NON-SMALL CELL CANCER

为研究CDK4I／P16与非小细胞肺癌的发生及发展的关系，应用免疫组化LSAB法研究了83例肺癌手术标本中CDK4I蛋白的表达。结果显示，CDK4I蛋白表达平均阳性率为65．93％。CDK4I蛋白表达与肺癌的临床分期、组织学分类、肺癌原发部位及有淋巴结转移的原发灶与无转移的原发灶之间比较无显著差异（P＞0．05），中－高分化的肺癌（77．95％）与低分化的肺癌（53．05％）之间有显著差异（P＜0．01）；肺癌的原发灶（64．16％）与相应的转移灶（淋巴结）（53．66％）之间有显著差异（P＜0．01）。肿瘤大小T1＋T2（68．90％）与T3＋T4（60．83％）之间差异显著（P＜0．05）。本研究结果表明CDK4I蛋白检测可以作为人非小细胞肺癌的抑制基因，并可能是肺癌术后预后的重要指标之一。

Using labe1led streptavidin - biotin (LSAB) methed, we exandned the expression of cyclin- dependent kinases 4 inhibitor P 16 (CDK4I ) in 83 cases of human non-sman cull lung cancer,the average rate of P16 protein positive expression was 65. 93 %. The positive expression were higher in mederate-weU differentiated of tumor cell(77. 95 % ) than inopr differentia 0ne (53. 05 % ) (P<0. 01 ), higher incidnce of P16 positive expression were found in prirnary lesions(64.1 6% ) than in metastatc lesions (the metastatic cancer of lymph nede) (53. 66% ).There were abo significant differencesbetween T1 +T2(68. 90 % ) in tumor size and T3 +T4 (60. 83% ) in. There were not significant differentiation among theclinical stage, between the pathological types of the carcinoma primary sites,between metastatic status of lymph nede,andpetients ages(P>0.05 ). The results suggest that CDK4I/P16 gene may be the suppressor gene in human non-small celllung cancer It may be a key index diagnosis of postoperative patients of lung cancer.